CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年4月6日～2025年4月12日の間に収集した論文情報を追加しました。

  1. Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance.

  レカネマブの長期的な安全性確認が重要

  対象DB：FAERS

  2. Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

  33種類の薬剤に腎結石のリスクが新たに確認

  対象DB：FAERS

  3. A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol.

  マンニトール使用時の高浸透圧状態や高ナトリウム血症に注意が必要

  対象DB：FAERS

  4. Dementia-related adverse events associated with direct oral anticoagulants use: a real-world, pharmacovigilance study based on the FAERS database.

  アピキサバンは認知症関連の副作用が最も多い

  対象DB：FAERS

  5. Pharmacovigilance study of immunomodulatory drug-related adverse events using spontaneous reporting system databases.

  IMiDの副作用は国別で異なり、患者の安全管理が重要

  対象DB：FAERS,JADER

  6. Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024.

  薬剤による帯状疱疹の発生には免疫抑制剤が関連

  対象DB：FAERS

  7. Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.

  抗HER-2薬は各薬剤で副作用の影響が異なる

  対象DB：FAERS

  8. Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System.

  デウクラバシチニブの副作用に皮膚障害や感染症

  対象DB：FAERS

  9. Ophthalmotoxicity induced by antibody-drug conjugates: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).

  抗体薬物複合体で眼毒性の報告が増加

  対象DB：FAERS

  10. Analysis of adverse events induced by fluconazole based on FAERS database.

  フルコナゾールで新たな副作用45件確認

  対象DB：FAERS

  11. Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database.

  IBS-D治療薬で薬剤特異的な重篤副作用確認

  対象DB：FAERS

  12. A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.

  GLP-1作動薬で湿疹、脱毛等皮膚障害を報告

  対象DB：FAERS

  13. Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data.

  ロミプロスチムが有効性高く、アバトロンボパグは安全性優位

  対象DB：FAERS

  14. Real-World Pharmacovigilance Analysis of Adverse Events Associated with Liposomal Bupivacaine and Bupivacaine.

  リポソーマルブピバカインに心・神経系の新規リスク

  対象DB：FAERS

  15. The adverse reactions of bevacizumab in combination with the FOLFOX chemotherapy regimen in metastatic colorectal cancer.

  フォルフォックス＋ベバシズマブ療法は感染症や消化器障害に関連

  対象DB：FAERS

  16. A real-world disproportionality analysis of cidofovir from the FDA Adverse Event Reporting System (FAERS) database.

  シドフォビルで腎障害の有害事象が最多

  対象DB：FAERS

  17. Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.

  セマグルチドで視覚障害報告が有意に多い

  対象DB：FAERS

  18. Drug-induced hearing loss: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

  1300薬剤の聴覚障害報告を整理し、432にシグナル

  対象DB：FAERS

  19. Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System.

  RSVpreFワクチン接種後、妊娠中の早産リスクに関する警告

  対象DB：CVAR,FAERS,VAERS

  20. Characteristics of second primary malignancies following bispecific antibodies therapy.

  BsAb治療後の二次原発性悪性腫瘍リスクを評価

  対象DB：FAERS

  21. Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.

  FAERSでPI薬の新たな有害事象を検出

  対象DB：FAERS

  22. Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping.

  FAERS全体で重複報告500万件特定

  対象DB：FAERS

  23. Safe CAR-T: shedding light on CAR-related T-cell malignancies.

  CAR-T後のT細胞腫瘍で警告強化

  対象DB：FAERS

  24. Paroxysmal sympathetic hyperactivity and cerebral salt wasting post management of arteriovenous malformation in a pediatric patient: A case report.

  小児ICH後にPSHとCSWを合併

  対象DB：JADER

  25. Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions.

  セファロキシム即時型アレルギーの検討

  対象DB：EudraVigilance

  26. Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study.

  Vaxzevriaの血栓症リスクとベネフィット評価

  対象DB：EudraVigilance

  27. Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.

  S1PRMsでのリンパ球減少に注意喚起

  対象DB：EudraVigilance

  28. EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding.

  授乳薬物副作用報告は少なく過小報告懸念

  対象DB：EudraVigilance

  29. Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance.

  腎障害は致死率高く、併用薬に注意

  対象DB：EudraVigilance

  30. Gambling disorders and drugs: a disproportionality analysis in the WHO pharmacovigilance database.

  一部薬剤でギャンブル障害のシグナル検出

  対象DB：VigiBase

  31. Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase((R)).

  高齢者・多剤併用で重篤副作用が増加

  対象DB：VigiBase

  32. Global burden of antidepressant-associated seizures from 1967 to 2023: A comparative analysis of the international pharmacovigilance database.

  発作リスクは薬剤間で大きく異なる

  対象DB：VigiBase

  33. Disproportionality analysis of cardiac adverse events associated with sorafenib using Spontaneous Reporting Database in Japanese.

  ソラフェニブで心障害が持続的に発現

  対象DB：JADER

  34. Development and validation of a distributed representation model of Japanese high-dimensional administrative claims data for clinical epidemiology studies.

  分散表現で未測定交絡を補正可能

  対象DB：DPC

  35. Antimicrobial prophylaxis with ampicillin/sulbactam versus cefazolin for orthopedic implant-related surgical site infections: A retrospective cohort study.

  ABPC/SBTはSSI予防に有効で安全

  対象DB：DPC

  36. Comparative Clinical Practice of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis in Adolescents and Young Adults: A Retrospective Cohort Study Using Japanese Health Insurance Claims Data (2016-2020).

  JIA患者はRAより薬剤費が高く、バイオ薬使用率も高い

  対象DB：JMDC

  37. Nationwide analysis of pelvic and acetabular fracture surgeries in Japan: The impact of aging and healthcare resources.

  骨盤・寛骨臼骨折ORIFは高齢女性で増加傾向

  対象DB：NDB

  38. Estimating the incidence of actionable drug-gene interactions in Japanese patients with major depressive disorder.

  抗うつ薬使用の25%に薬理遺伝学的介入が有効

  対象DB：MDV

  39. Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern Ireland.

  喘息・COPDは減少、ILDは増加傾向

  対象DB：CPRD

  40. Effect of intra-articular corticosteroid injections for knee osteoarthritis on the rates of subsequent knee replacement and post-operative outcomes: a national cohort study of England.

  関節内注射は置換術リスクを低減

  対象DB：CPRD

  41. Predictors of persisting symptoms after concussion in children following a traumatic brain injury: a longitudinal retrospective cohort study.

  脳震盪後症状は年長・女性・既往歴で多発

  対象DB：CPRD

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み